Skip to main content

Advertisement

Table 4 Clinical studies in Lung Cancer

From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Patients Trial, ID Follow-up Outcomes Reference
Advanced NSCLC Phase 1b
NCT02000947
24 weeks ORR, 23%
Grade 3-4 AEs, 35%
Antonia et al 2016
Treatment relapsed advanced SCLC Phase 1/2
NCT01928394
≥ 12 weeks ORR, 23%
Median OS, 7.7 months
1-year OS rate, 43%
Median PFS, 2.6 months
1-year PFS rate, 19%
Grade 3-4 AEs, 30%
Antonia et al 2016
Untreated advanced NSCLC Phase 1 NCT01454102 > 9 months ORR, 47%
Median PFS, 8.1 months
24-week PFS rate, 68%
Grade 3-4 AEs, 37%
Hellman et al 2017
Untreated advanced NSCLC Phase 2
NCT02659059
≥ 6 months In patients with TMB≥10 mutations/megabase
ORR, 44%
Median PFS, 7.1 months
6-month PFS rate, 55%
Grade 3-4 AEs, 29% (all patients)
Ready et al 2019
Untreated advanced NSCLC Phase 3
NCT02477826
> 11 months In patients with TMB≥10 mutations/megabase
ORR, 45%
Median PFS, 7.2 months
12-month PFS rate, 43%
HR for disease progression or death, 0.58
Grade 3-4 AEs, 31%
Hellman et al 2018